Published in Parkinsonism Relat Disord on October 25, 2012
Urdu Version of the Unified PARKINSON Disease Rating Scale | NCT04569552
Randomized controlled clinical trial of "virtual house calls" for Parkinson disease. JAMA Neurol (2013) 1.24
High patient satisfaction with telehealth in Parkinson disease: A randomized controlled study. Neurol Clin Pract (2016) 0.83
Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials (2014) 0.83
Remotely Assessing Symptoms of Parkinson's Disease Using Videoconferencing: A Feasibility Study. Neurol Res Int (2016) 0.75
Feasibility of Virtual Research Visits in Fox Trial Finder. J Parkinsons Dis (2015) 0.75
The measurement of observer agreement for categorical data. Biometrics (1977) 216.56
Intraclass correlations: uses in assessing rater reliability. Psychol Bull (1979) 71.07
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. JAMA (2000) 4.10
Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology (2008) 3.10
Predictors of future falls in Parkinson disease. Neurology (2010) 3.00
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
How redesigning AD clinical trials might increase study partners' willingness to participate. Neurology (2008) 1.74
Comparison of office-based versus home Web-based clinical assessments for Parkinson's disease. Mov Disord (2011) 1.56
Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord (2010) 1.50
Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge. Parkinsonism Relat Disord (2011) 1.05
Telemedicine for the care of nursing home residents with Parkinson's disease. Mov Disord (2009) 0.93
Responsiveness of impairments and disabilities in Parkinson's disease. Parkinsonism Relat Disord (2006) 0.89
Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 56.72
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA (2013) 10.43
Financial anatomy of biomedical research. JAMA (2005) 7.49
The anatomy of health care in the United States. JAMA (2013) 2.58
NIH disease funding levels and burden of disease. PLoS One (2011) 2.56
Biomedical research in an age of austerity. JAMA (2012) 2.52
Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS. Neurology (2013) 2.45
Neurocognitive signs in prodromal Huntington disease. Neuropsychology (2011) 2.14
Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care (2012) 1.91
Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's disease. Mov Disord (2010) 1.50
Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol (2009) 1.34
A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groups. Mov Disord (2010) 1.28
Randomized controlled clinical trial of "virtual house calls" for Parkinson disease. JAMA Neurol (2013) 1.24
Local institutional review board (IRB) review of a multicenter trial: local costs without local context. Ann Neurol (2010) 1.23
Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr (2012) 1.15
Characterization of a large group of individuals with huntington disease and their relatives enrolled in the COHORT study. PLoS One (2012) 1.14
Fear of health insurance loss among individuals at risk for Huntington disease. Am J Med Genet A (2008) 1.12
Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci (2013) 1.10
A randomized, placebo-controlled trial of latrepirdine in Huntington disease. Arch Neurol (2010) 1.10
Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol (2009) 1.06
The past, present, and future of telemedicine for Parkinson's disease. Mov Disord (2014) 0.97
Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett (2012) 0.97
Telemedicine for the care of nursing home residents with Parkinson's disease. Mov Disord (2009) 0.93
Restless legs syndrome and drug-induced akathisia in headache patients. CNS Spectr (2003) 0.90
Altered cholesterol and fatty acid metabolism in Huntington disease. J Clin Lipidol (2010) 0.88
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv (2013) 0.86
Caring for the majority. Mov Disord (2013) 0.86
The benefits of exercise in Parkinson disease. JAMA Neurol (2013) 0.84
The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Hum Gene Ther (2002) 0.84
Virtual house calls for Parkinson disease (Connect.Parkinson): study protocol for a randomized, controlled trial. Trials (2014) 0.83
Telemedicine in Leading US Neurology Departments. Neurohospitalist (2012) 0.83
Willingness of Parkinson's disease patients to participate in research using internet-based technology. Telemed J E Health (2012) 0.81
Opsoclonus-myoclonus syndrome and exaggerated startle response associated with small-cell lung cancer. Mov Disord (2011) 0.80
The eyes as a window into disease prevention. Neurology (2006) 0.79
The return of the house call. Ann Intern Med (2015) 0.78
Hyperphosphatasia with neurologic deficit: a pyridoxine-responsive seizure disorder? Pediatr Neurol (2006) 0.78
Tapping in Huntington disease: a path forward to preventive therapies? Neurology (2010) 0.77
Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches? Mov Disord (2014) 0.77
Web-based clinical assessments for Parkinson's disease: reliable and feasible. Mov Disord (2012) 0.76
8-OHdG: its (limited) potential as a biomarker for Huntington's disease. Biomark Med (2012) 0.76
Funding for biomedical research--reply. JAMA (2013) 0.75
Reply: An exploration of the burden experienced by spousal caregivers of individuals with Parkinson's disease. Mov Disord (2010) 0.75
Quality of life in epilepsy, multiple sclerosis, and beyond. Ann Neurol (2007) 0.75
Impact of alternative medical device approval processes on costs and health. Clin Transl Sci (2014) 0.75
Author Response. Neurology (2015) 0.75
Next Generation House Call. Cerebrum (2017) 0.75